INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Patent applications |
Patent application number | Title | Published |
20160066551 | NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS - The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal. | 03-10-2016 |
20160054338 | Methods for Predicting Cardiovascular Mortality Risk - The present invention relates to a method for predicting cardiovascular mortality risk in a patient, comprising determining the level of endothelial microparticles in a blood sample obtained from said patient. | 02-25-2016 |
20160038569 | PARTICLES CONTAINING A GROWTH FACTOR, AND USES THEREOF - The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof. | 02-11-2016 |
20160031943 | COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS - The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus. | 02-04-2016 |
20160017035 | TIM RECEPTORS AS VIRUS ENTRY COFACTORS - The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TIM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as | 01-21-2016 |
20160015808 | TAM RECEPTORS AS VIRUS ENTRY COFACTORS - The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TAM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as flavivirus infection. | 01-21-2016 |
20160015773 | INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF - The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis. | 01-21-2016 |
20160002730 | METHOD FOR CLASSIFYING AN INFLAMMATORY BOWEL DISEASE AS A CROHN'S DISEASE OR AS AN ULCERATIVE COLITIS - The present invention relates to a method for classifying an inflammatory bowel disease in a patient as a Crohn's disease or as an ulcerative colitis, said method comprising a step of measuring an expression profile of miRNA in a sample from the patient, wherein said miRNA are miR15a, miR26a, miR29a, miR29b, miR30c, miR126*, miR127-3p, miR-142-3p, miR-142-5p, miR-146a, miR-146b-5p, miR150, miR-181d, miR-182, miR185, miR196a, miR199a-3p, miR199a-5p, miR199b-5p, miR-203, miR223, miR-299-5p, miR320a, miR324-3p, miR-328. | 01-07-2016 |
20150377892 | DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS - The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperon activity and/or is not capable of binding to best-shock protein 70 (HSP70) and/or to beat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat-shock protein 110 can be used (i) in methods for proposing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers. | 12-31-2015 |
20150369811 | METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER - The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis. | 12-24-2015 |
20150368715 | DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE - The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure. | 12-24-2015 |
20150353643 | ANTI-CD277 ANTIBODIES AND USES THEREOF - Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described. | 12-10-2015 |
20150342876 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES - The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease. | 12-03-2015 |
20150328365 | POROUS POLYSACCHARIDE SCAFFOLD COMPRISING NANO-HYDROXYAPATITE AND USE FOR BONE FORMATION - The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stent cells or growth factors. | 11-19-2015 |
20150307887 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS - The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders. | 10-29-2015 |
20150293126 | Method for Diagnosing a Hemoglobin-Related Disorder - The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as β-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free α-Hb pool in a biological sample obtained from said subject. | 10-15-2015 |
20150291691 | METHODS FOR CANCER MANAGEMENT TARGETING CO-029 - The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient. | 10-15-2015 |
20150291669 | Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof - Recombinant | 10-15-2015 |
20150250770 | LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER - Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample previously taken from a breast cancer patient, Classifying the breast cancer as likely to respond to treatment with everolimus if the LKB1 gene is under-expressed in said breast tumour sample. | 09-10-2015 |
20150226749 | METHOD FOR ASSESSING A SUBJECT'S RISK OF HAVING A CARDIOVASCULAR DISEASE - The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease. | 08-13-2015 |
20150225799 | METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION - The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient. | 08-13-2015 |
20150216891 | NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS - The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer. | 08-06-2015 |
20150104463 | METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT - The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject. | 04-16-2015 |
20150099013 | Sodium Thiosulphate for the Treatment of Ectopic Calcifications - The present invention relates to pharmaceutical compositions comprising sodium thiosulphate dispersed in a hydrophile-in-lipophile emulsion, and the use thereof for topical administration for the treatment of an ectopic calcification and/or of the consequences thereof in an individual, the sodium thiosulphate being in the form of a pharmaceutical composition comprising, in addition, a hydrophile-in-lipophile emulsion. The invention also relates to a method for preparing these pharmaceutical compositions. | 04-09-2015 |
20150050264 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF - The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | 02-19-2015 |
20150018383 | BIOMARKERS OF RENAL DISORDERS - The present invention is directed to the use of marker for Akt2 activation in podocytes as a biomarker to predict toxicity of mTOR inhibitors. Another aspect of the invention relates to a method for preventing graft rejection comprising administering a selective mTORC1 or Akt1 inhibitor in a subject in need thereof. | 01-15-2015 |
20140377379 | METHOD FOR PROGNOSING THE AGE-AT-ONSET OF HUNTINGTON'S DISEASE - The present invention relates to the prediction of the age-at-onset of Huntington's disease. More specifically, it relates to the use of at least one FoxO-centered network related biallelic markers, preferably single nucleotide polymorphism (SNP) markers, in particular GSK-3β and/or TCERG1 and/or FOXO1 and/or FZD10 related biallelic markers, for prognosing the age-at-onset of symptoms of Huntington's disease in an individual at risk of suffering from said disease. The invention also relates to lithium or a salt thereof for use at low doses in the treatment or prevention of Huntington's disease | 12-25-2014 |
20140373186 | NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS - The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal. | 12-18-2014 |
20140335119 | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41. | 11-13-2014 |
20140329261 | TREATMENT OF CANCER BY INHIBITION OF THE MYD88/ERK MAP KINASE INTERACTION - A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE. | 11-06-2014 |
20140328893 | NUTLIN COMPOUNDS FOR USE IN THE TREATMENT OF PULMONARY HYPERTENSION - The present invention relates to uses, methods and compositions for the treatment of pulmonary hypertension. | 11-06-2014 |
20140322235 | ANTI-CD277 ANTIBODIES AND USES THEREOF - The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy. | 10-30-2014 |
20140316372 | DEVICE FOR THE TREATMENT OF AN OCULAR DISEASE - An electrode device having an insertion part ( | 10-23-2014 |
20140316326 | DEVICE FOR THE TREATMENT OF AN OCULAR DISEASE - The present invention relates to an injection device comprising: —a first support ( | 10-23-2014 |
20140309613 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT - The present invention relates to a method for treating an ocular disease in a subject comprising the steps consisting of i) delivering a pharmaceutical composition formulated with a therapeutic nucleic acid of interest into the suprachoroidal space of the diseased eye and ii) exposing the region where the pharmaceutical composition was delivered to an electrical field. | 10-16-2014 |
20140308665 | DIAGNOSIS OF HEREDITARY SPASTIC PARAPLEGIAS (HSP) BY DETECTION OF A MUTATION IN THE KIAA1840 GENE OR PROTEIN - An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP). | 10-16-2014 |
20140286996 | Modified Gram-Negative Bacteria For Use As Vaccines - The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host. | 09-25-2014 |
20140286901 | Methods, Pharmaceutical Compositions and Kits for Use in the Treatment of Adult T-Cell Leukemia/Lymphoma - The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma. | 09-25-2014 |
20140271563 | EFFECT OF AN ATTENUATED BORDETELLA STRAIN AGAINST ALLERGIC DISEASE - Described herein are compositions, vaccines, and methods that include use of a mutated | 09-18-2014 |
20140249121 | METHODS AND KITS FOR DETECTING CARDIAC REMODELING IN SUBJECTS WITHOUT CLINICAL SIGNS OF HEART FAILURE - The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient. | 09-04-2014 |
20140235557 | Small Efficient Cell Penetrating Peptides Derived From The Scorpion Toxin Maurocalcine - The invention relates to small cell penetrating peptides (CPP) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents. | 08-21-2014 |
20140221462 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CARDIOMYOPATHY DUE TO FRIEDREICH ATAXIA - A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN). | 08-07-2014 |
20140212406 | NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF - The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases. | 07-31-2014 |
20140206601 | Methods and Pharmaceutical Compositions for the Treatment of Respiratory Tract Infections - The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection. | 07-24-2014 |
20140205568 | Promyelocytic Leukemia Protein as a Redox Sensor - The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue. | 07-24-2014 |
20140199763 | COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS - Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C. | 07-17-2014 |
20140199326 | Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders - The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject. | 07-17-2014 |
20140186960 | Non Human Animal Models for Increased Retinal Vascular Permeability - The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates to methods and compositions for the treatment of a disease associated with an increased retinal vascular permeability in a subject in need thereof. | 07-03-2014 |
20140186829 | METHOD FOR PREDICTING INSULINOPENIC TYPE 2 DIABETES - The present invention relates to an in vitro method, for predicting a risk of onset of type 2 diabetes in a subject, which method comprises the steps of: a) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) comparing said measured concentration of bacterial 16S rDNA to a threshold level; wherein a measured concentration of bacterial 16S rDNA higher than the threshold level is indicative of an increased risk of onset of type 2 diabetes in the subject, and a measured concentration of bacterial 16S rDNA lower than the threshold level is indicative of a decreased risk of onset of type 2 diabetes in the subject. | 07-03-2014 |
20140179687 | New Inhibitors of Cyclophilins and Uses Thereof - The present invention relates to a compound of formula (I): | 06-26-2014 |
20140178922 | SELECTIVE CULTURE MEDIUM AND METHOD FOR DETECTING CARBAPENEM-RESISTANT BACTERIA IN A TEST SAMPLE - The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium. | 06-26-2014 |
20140178308 | METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL - The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma. | 06-26-2014 |
20140163021 | FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction - Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding. | 06-12-2014 |
20140161775 | SILYLATED BIOMOLECULE-BASED HYDROGEL FOR CULTURING CARDIOMYOCYTES AND STEM CELLS, AND USE OF THE HYDROGEL THEREOF FOR TREATING HEART FAILURE - The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction. | 06-12-2014 |
20140154213 | RECOMBINANT VECTOR FOR PRODUCING AND SECRETING PEPTIDE OR PROTEIN OF INTEREST BY PROPIONIBACTERIA AND APPLICATIONS THEREOF - The present invention relates to a recombinant vector for expressing and secreting, by a | 06-05-2014 |
20140142168 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HORMONE-REFRACTORY PROSTATE CANCERS - The present invention relates to a combination of a curcuminoid and a taxane for use in the treatment of a hormone-refractory prostate cancer (HRPC) in a patient in need thereof. | 05-22-2014 |
20140141442 | LINEAR DNA AMPLIFICATION - The present invention provides materials and methods for DNA amplification, in particular linear amplification methods using RNA polymerase. These methods permit high-throughput sequencing of pictogram amounts of DNA and are of use in a range of applications including genome-wide profiling of transcription factors and epigenetic DNA and histone modifications, global transcript profiling, mapping of chromatin conformations, as well as for forensic use and archaeological studies. | 05-22-2014 |
20140128337 | Curcuminoids in Combination Docetaxel for the Treatment of Cancer and Tumour Metastasis - The present invention relates to a curcuminoid for enhancing the clinical efficacy of Docetaxel for the treatment of cancers and metastases. | 05-08-2014 |
20140127180 | MUTANT CYTOCHROME P450 2B6 PROTEINS AND USES THEREOF - The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy. | 05-08-2014 |
20140121167 | THERAPEUTIC PEPTIDES AND USE THEREOF AGAINST HUNTINGTON'S DISEASE - Novel therapeutic compounds for use against Huntington's disease. More especially, an isolated peptide of size less than 100 amino acids and containing:
| 05-01-2014 |
20140093884 | Process for Identifying Novel Anti-Inflammatory Molecules with Reduced Direct Transrepression of Genes Induced by Glucocorticoids - The present invention relates to a new process for identifying novel anti-inflammatory molecules with reduced direct transrepression of genes induced by glucocorticoids. | 04-03-2014 |
20140093453 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS - The present invention relates to the compound of formula (I): | 04-03-2014 |
20140088203 | METHOD FOR PREDICTING ABDOMINAL OBESITY - The present invention relates to a method, in particular an in vitro method, for predicting a risk of onset of abdominal obesity in a subject, which method comprises the steps of: a1) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) based on the result of the measurement in step a1), determining a risk of onset of abdominal obesity in the subject. | 03-27-2014 |
20140086954 | USE OF BLOOD OR TISSUE BACTERIOME FOR PREDICTION, DIAGNOSIS AND PREVENTION OF METABOLIC DISEASES AND THEIR CARDIOVASCULAR COMPLICATIONS - The present invention relates to the use of the bacterial flora for vaccine development, identification of therapeutic targets and prediction and/or diagnosis of metabolic diseases, such as diabetes, overweight and obesity, and their cardiovascular complications. In particular, the present invention provides immunogenic or vaccinal composition for preventing metabolic diseases and cardiovascular complications using attenuated or inactivated bacterial flora, or antigens derived thereof. The present invention also provides methods for identifying prognostic markers for metabolic diseases onset and cardiovascular complications and methods for in vitro prognosis of metabolic diseases and cardiovascular complications using bacterial flora. | 03-27-2014 |
20140086895 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune diseases, especially rheumatoid arthritis. More particularly, the present invention relates to an a-enolase polypeptide for use in the prophylactic treatment of an autoimmune disease in a subject in need thereof. | 03-27-2014 |
20140072573 | METHOD OF TREATING RHEUMATOID ARTHRITIS - The invention relates to a method of treating rheumatoid arthritis in a patient comprising the steps of: | 03-13-2014 |
20140050710 | METHODS FOR PREPARING ACCESSORY CELLS AND USES THEREOF FOR PREPARING ACTIVATED NK CELLS - The present invention relates to a method for preparing accessory cells, said accessory cells may themselves be used for preparing activated NK cells that may be used in various therapeutic protocols (e.g. cancer treatment). More particularly, the present invention relates to a method for preparing an accessory cell comprising the steps consisting of i) providing a cell and ii) inhibiting in said cell the expression of a gene encoding for a Killer-Cell Immunoglobulin-like Receptor(s) (KIR) ligand. | 02-20-2014 |
20140038900 | DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS - The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperone activity and/or is not capable of binding to heat-shock protein 70 (HSP70) and/or to heat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP 110. Such a mutated heat-shock protein 110 can be used (i) in methods for prognosing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers. | 02-06-2014 |
20140031276 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION - A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided. | 01-30-2014 |
20140025098 | DEVICE FOR OCULAR ULTRASOUND THERAPY HAVING A REFLECTOR - The present invention relates to a device for treating an ocular pathology, including a ring ( | 01-23-2014 |
20140024627 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES - The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease. | 01-23-2014 |
20140024101 | METHOD FOR INCREASING THE REPLICATION CAPACITY OF AN INFLUENZA VIRUS IN CULTURED CELLS - The present invention relates to methods for increasing the replication capacity of an influenza virus in cultured cells. More particularly, the present invention relates to a method for increasing the replication capacity of an influenza virus in a cell comprising the steps consisting of i) infecting said cell with said influenza virus and ii) culturing said infected cell with a least one molecule selected from the group consisting of Dibucaine, Aprindine, Amiloride, Mevinolin, Simvastatin, Promathazine, Pranlukast, Nimodipine, Ibutilide hemifumarate Salt, Risperidone and derivatives or analogues thereof. | 01-23-2014 |
20140024018 | METHOD FOR THE PROGNOSIS OF PROGRESSION OF THE HIV DISEASE - An in vitro method for the prognosis of progression of an HIV-1 infection in a patient infected with an HIV-1 virus, comprising the steps of: a) measuring the level of antibodies directed against the 3S peptide of SEQ ID NO 2 in a sample collected from the said patient, b) comparing the level of anti-3S antibodies measured at step a) with a reference value of anti-3S antibody level that is indicative of the progression of the HIV-1 infection. | 01-23-2014 |
20140023675 | SULPHATED ARABINOGALACTANS, APIOGALACTURONANS AND SULPHATED HETEROGLYCANS FOR TREATING DISEASES CAUSED BY THE INFLUENZA VIRUS - The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier:
| 01-23-2014 |
20140018255 | METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION - The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient. | 01-16-2014 |
20140005156 | AMINOALKYLSTEROL COMPOUNDS WITH ANTITUMORAL AND NEUROPROTECTIVE ACTIVITY | 01-02-2014 |
20130345145 | ATIP3 AND BIOLOGICALLY ACTIVE FRAGMENTS THEREOF FOR USE IN THE TREATMENT OF CANCER - The present invention concerns a combination of (i) a polypeptide comprising ATIP3 or a biologically active fragment thereof, and (ii) a chemotherapeutic drug that is an antimitotic agent, for simultaneous or sequential use in the treatment of a patient suffering from cancer, e.g. a triple-negative breast cancer. The present invention also relates to a polypeptide comprising ATIP3 or a biologically active fragment thereof, for use in sustaining drug effect, increasing or restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug that is an anti-mitotic agent. The present invention further provides biologically active polypeptides that comprise or consist of fragments of ATIP3, and antibodies binding thereto. | 12-26-2013 |
20130324595 | C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION - The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell. | 12-05-2013 |
20130316382 | METHOD FOR EVALUATING THE VITAL PROGNOSIS OF A SUBJECT IN A CRITICAL CONDITION - The invention relates to a method for evaluating the vital prognosis of a subject suffering from heart failure, said method comprising the step of determining the lactate/cholesterol ratio in a biological sample of said subject and comparing the lactate/cholesterol ratio to a threshold value. | 11-28-2013 |
20130310401 | METHOD AND KITS FOR DETERMINING PLATELET SUSCEPTIBILITY TO ACTIVATION IN A PATIENT - The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient. | 11-21-2013 |
20130310275 | DIAGNOSIS OF ASYMPTOMATIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION - The invention relates a method for diagnosing asymptomatic left ventricular systolic dysfunction in a subject comprising the step a) of: —measuring the level of expression of the genes FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject; or—measuring the level of expression of at least one gene selected from the group consisting of FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject. | 11-21-2013 |
20130303439 | CHIMERIC PEPTIDES INCLUDING A PENETRATING PEPTIDE AND A BINDING DOMAIN OF PP2A CATALYTIC SUBUNIT TO CASPASE-9 - The invention related to chimeric peptides including a penetrating peptide and a binding domain of PP2A catalytic subunit to caspase-9 which have pro-apoptotic activity. These chimeric peptides may be used for the treatment of hyperproliferative disorders. | 11-14-2013 |
20130287808 | VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS - The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2AP) and type IV pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type IV pilus-associated proteins and the β2AP. | 10-31-2013 |
20130261535 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT - A method of treating an ocular disease in a subject includes delivering a pharmaceutical composition into a ciliary muscle of the subject and inducing transfection of the therapeutic nucleic acid into the ciliary muscle by exposing the pharmaceutical composition to ultrasound. The pharmaceutical composition comprises echo-contrast agent microbubbles and a therapeutic nucleic acid. | 10-03-2013 |
20130261060 | Serene Protease Derivatives and Uses in the Prevention or the Treatment of Blood Coagulation Disorders - The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders. | 10-03-2013 |
20130224277 | POROUS POLYSACCHARIDE SCAFFOLD COMPRISING NANO-HYDROXYAPATITE AND USE FOR BONE FORMATION - The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stem cells or growth factors. | 08-29-2013 |
20130224192 | METHOD FOR THE PROGNOSIS OF THE PROGRESSION OF CANCER - The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a cancer, in particular with a breast cancer, a lung cancer or other primary cancer, said methods comprising the step of detecting a higher expression level of FERMT1 gene in a tumour sample compared to a control reference values. The invention further relates to inhibitors of FERMT1 expression and their uses in the treatment of cancer or metastasis. | 08-29-2013 |
20130217717 | COMPOUND USEFUL FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND - The present invention relates to the compound of formula (I) | 08-22-2013 |
20130203648 | Preparation of Recombinant Human Plasma Phospholipid Transfer Protein (PLTP) From the Milk of Transgenic Animals - The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock. | 08-08-2013 |
20130189683 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 07-25-2013 |
20130177925 | DETECTION OF ANTIGEN-SPECIFIC PERIPHERAL BLOOD MONONUCLEAR CELLS AND METHODS FOR DIAGNOSING IMMUNE DISORDERS - The present invention relates to a method for detecting the presence or the absence, and optionally quantifying and/or isolating, antigen-specific peripheral blood mononuclear cells. This method, which involves flow cytometry, is based on the use of a fluorescently-labeled antibody specifically recognizing peripheral blood mononuclear cells, and of fluorescently-labeled beads coated with at least one antigen that is specifically recognized by antigen-specific peripheral blood mononuclear cells. The method according to the invention is for example useful for diagnosing immune disorders such as transplant rejections and autoimmune disorders. | 07-11-2013 |
20130172901 | TOOL FOR INSERTING FINE TUBULAR OBJECTS INTO THE COCHLEA - A tool for inserting fine tubular objects into the cochlea is provided. The tool has a gripping body, which forms a handle and ends in a tubular guide for the fine tubular object, and a pusher engaged in the tubular guide in order to push the fine tubular object out of the guide and into the cochlea. The tool is equipped with: an electronic control unit; motorized means controlled by the control unit in order to move the pusher; a force-measuring means connected to the control unit and arranged so as to be sensitive to a resistance force experienced by the fine tubular object during insertion into the cochlea and supplying a signal that can be exploited in order to estimate the resistance force; and means for indicating the resistance force connected to the control unit. | 07-04-2013 |
20130156702 | METHODS FOR THE TREATMENT AND THE DIAGNOSIS OF CANCER - The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver cancer such as hepatocellular carcinoma (HCC). | 06-20-2013 |
20130150304 | TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL DEGENERATIVE DISORDER - Treatment of a disease associated with retinal degenerative disorder. The present invention relates to human Transferrin or an active fragment thereof for use in the treatment of a disease associated with retinal degenerative disorder. | 06-13-2013 |
20130143850 | METHODS AND COMPOSITIONS FOR STIMULATING REEPITHELIALISATION DURING WOUND HEALING - The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing. | 06-06-2013 |
20130143764 | METHOD FOR CLASSIFYING AN INFLAMMATORY BOWEL DISEASE AS A CROHN'S DISEASE OR AS AN ULCERATIVE COLITIS - The present invention relates to a method for classifying an inflammatory bowel disease in a patient as a Crohn's disease or as an ulcerative colitis, said method comprising a step of measuring an expression profile of miRNA in a sample from the patient, wherein said miRNA are miR15a, miR26a, miR29a, miR29b, miR30c, miR126*, miR127-3p, miR-142-3p, miR-142-5p, miR-146a, miR-146b-5p, miR150, miR-181d, miR-182, miR185, miR196a, miR199a-3p, miR199a-5p, miR199b-5p, miR-203, miR223, miR-299-5p, miR320a, miR324-3p, miR-328. | 06-06-2013 |
20130079663 | Device for Transiently Contacting At Least One Unit For Capturing Biological Targets With A Fluid Containing Them, Method For Recovering The Captured Targets And System For Contacting And Recovery - The invention relates to a device for transiently contacting at least one unit for capturing biological targets with a body fluid containing them, a method for recovering the captured targets for analysis, and a system for contacting and recovering a capture substrate included in said unit. The invention relates to samples obtained in particular in vivo from body fluids of the human body, e.g. circulating body fluids, said fluids possibly containing, as targets, proteins, oligonucleotides such as RNA or DNA, antibodies, enzymes or cells. A contacting device ( | 03-28-2013 |
20120321650 | COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - Epitopes derived from a protein present in an atherosclerotic plaque, such as apolipoprotein B-100, are presented. The epitopes can be used in a method of treating atherosclerosis by continuous subcutaneous or transcutaneous administration of a therapeutically effective amount of the epitope to a subject. Administering the epitope to the subject can induce a specific regulatory immune response, such as a Treg response. A composition or patch containing the epitope and adapted for the prophylactic or therapeutic treatment of a subject are also presented. | 12-20-2012 |
20120302517 | TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour. | 11-29-2012 |
20120301465 | COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS - Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C. | 11-29-2012 |
20120258093 | VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY - The invention relates to methods for the treatment of Duchenne muscular dystrophy and to methods for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy. More particularly, the present invention relates to a VLA-4 antagonist for use in the treatment of Duchenne Muscular Dystrophy. The present invention also relates to a method for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy wherein said method comprising a step consisting of determining the level of VLA-4 high T cells in a blood sample obtained from said subject. | 10-11-2012 |
20120244155 | Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine - Compositions and methods comprising high affinity monoclonal antibody conjugates against several DC receptors are described herein. The inventors prepared fusion proteins with antigens for DC-targeting vaccine generation by conjugating several | 09-27-2012 |
20120238461 | METHOD FOR DETERMINING THE RISK OF OCCURRENCE OF ALZHEIMER'S DISEASE - The present invention relates to an in vitro method for determining that an individual is at risk of developing Alzheimer's disease, which comprises: —determining whether the individual harbours at least one variant allele of a susceptibility gene selected from the apolipoprotein J gene (APOJ) and the complement component receptor 1 gene (CR 1); —deducing that if the individual harbours at least one variant allele of the APOJ and/or CR1 gene, then the individual is at risk of developing Alzheimer's disease. | 09-20-2012 |
20120184557 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R | 07-19-2012 |
20120184480 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS - The invention relates to the use of oligomers having constrained dipeptide or tripeptide motifs as agents for the vectorization of active ingredients. | 07-19-2012 |
20120136281 | PARAMETERS FOR AN ULTRASOUND DEVICE COMPRISING MEANS TO GENERATE HIGH INTENSITY ULTRASOUND BEAM - The present invention relates to a device for treatment of an ocular pathology, the device comprising at least one eye ring ( | 05-31-2012 |
20120122873 | AMINO DERIVATIVES OF DIHYDRO-1,3,5-TRIAZINE USED IN THE TREATMENT OF ISCHEMIA AND/OR REPERFUSION RELATED DISEASES - The invention relates to amino derivatives of dihydro-1,3,5-triazine, used for the treatment and/or prevention of diseases induced by ischemia and/or reperfusion, notably cardiac and renal complications. | 05-17-2012 |
20120121647 | INFLUENZA VACCINE, COMPOSITION, AND METHODS OF USE - The invention relates to compositions and vaccines that include a mutated | 05-17-2012 |
20120093915 | VECTORS INCLUDING AN ANIONIC MACROMOLECULE AND A CATIONIC LIPID FOR DELIVERING SMALL NUCLEIC ACIDS - The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy. | 04-19-2012 |
20120066776 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 03-15-2012 |
20120058139 | NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY - A stabilized multimodular assembly for intracellular delivery comprising a complex of at least one cationic transfection agent and of at least one negatively charged macromolecule, wherein the complex has a theoretical charge ratio ranging from about 0 to about 4, and an efficient amount of at least one amphiphilic block co-polymer acting as a steric colloidal stabilizer with respect to the complex, the block co-polymer having hydrophilic and hydrophobic blocks wherein at least one hydrophilic block is conjugated with at least one targeting ligand. | 03-08-2012 |
20120040848 | MOLECULAR SIGNATURE OF LIVER TUMOR GRADE AND USE TO EVALUATE PROGNOSIS AND THERAPEUTIC REGIMEN - The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient. | 02-16-2012 |
20120040389 | METHOD FOR DEMONSTRATION OF A MOLECULAR EVENT IN A CELL BY MEANS OF FLUORESCENT MARKER PROTEINS - The invention relates to a method for demonstration of the occurrence of a molecular event, particularly in a cell, characterised by the detection of the ‘solubilisation’ of a fixed protein marker (or the fixing of a solubilised protein marker) which is a direct or indirect marker for the occurrence of the particular molecular event. Said protein marker is present in the cell before the above detection, the cell being subjected to a permeabilisation of the plasma membrane before detection, which liberates the solubilised protein into the extracellular medium, the presence of the marker protein thus being detected in the cell or the extra-cellular medium by any appropriate means, which permits the detection of whether the solubilisation, or the fixing have taken place and, hence, the corresponding molecular event. | 02-16-2012 |
20120027758 | USE OF ANTI-CD100 ANTIBODIES - The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells. | 02-02-2012 |
20120021012 | NOVEL PHARMACEUTICAL USES FOR NANOPARTICLES - The present invention relates to SiC nanoparticles to be used in the context of cancer treatment, said nanoparticles preferably having a size less than 100 nm. | 01-26-2012 |
20110313026 | DNA AND PROTEINS OR PEPTIDES SPECIFIC OF BACTERIA OF THE NEISSERIA MENINGITIDIS SPECIES, METHODS FOR OBTAINING THEM AND BIOLOGICAL APPLICATIONS THEREOF - The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in | 12-22-2011 |
20110311992 | Method of Prognosis and/or Diagnosing an IRS in a Patient Infected with M. Tuberculosis and Optionally HIV - The invention relates to a method of prognosing and/or diagnosing a | 12-22-2011 |
20110311544 | Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells - The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells. | 12-22-2011 |
20110301469 | ULTRASOUND DEVICE COMPRISING MEANS TO GENERATE ULTRASOUND BEAM PRESENTING A CONCAVE SEGMENT SHAPE HAVING A SINGLE CURVATURE - A device for treatment of an ocular pathology characterized in that it comprises at least one eye ring ( | 12-08-2011 |
20110286963 | HUMAN SOLUBLE CD146, PREPARATION AND USES THEREOF - The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells. | 11-24-2011 |
20110280866 | ANTI-CD 160 MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention concerns an antibody or fragment thereof, capable of binding to CD 160, said antibody comprising a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: (i) the light chain CDR1: QSISNH (SEQ ID NO: 1), (ii) the light chain CDR2: YAS, (iii) the light chain CDR3: QQSNSWPLT (SEQ ID NO: 2), and a light chain framework sequence from an immunoglobulin light chain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: (i) the heavy chain CDR1: GYTFTDYW (SEQ ID NO: 3), (ii) the heavy chain CDR2: IYPGDDDA (SEQ ID NO: 4); (iii) the heavy chain CDR3: ARRGIAAVVGGFDY (SEQ ID NO: 5); and a heavy chain framework sequence from an immunoglobulin heavy chain; a pharmaceutical comprising said antibody and the use of said antibody for preparation of a medicament for treating and/or preventing a pathology associated with endothelial cells proliferation engaged in an angiogenesis process. | 11-17-2011 |
20110275604 | AMINOALKYLSTEROL COMPOUNDS WITH ANTITUMORAL AND NEUROPROTECTIVE ACTIVITY - Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament. | 11-10-2011 |
20110263694 | Use of Xanthone Derivatives as a Medicament for Cancer - The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma. | 10-27-2011 |
20110263523 | TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour. | 10-27-2011 |
20110257176 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS - A method for treating and/or ameliorating and/or preventing a disease or a disorder, the method comprising administering to an individual in need thereof at least one nitrogen heterocycle derivative of formula (I): | 10-20-2011 |
20110201648 | POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER - The present invention relates to Penta-hexa-, hepta-, octa-, nona- and, deca-heteroaryl derivatives, comprising a combination of heterocycle 1 (Het-1) | 08-18-2011 |
20110178023 | Use Of SCO-Spondin Peptides For Inhibiting Or Preventing Neuronal Apoptosis Mediated By Cell Death Receptor Ligands - The invention relates to a polypeptide derived from the TSR (thrombospondin type 1 units) of SCO-Spondin for inhibiting or preventing the apoptosis mediated by the cell death receptor ligands, such as TRAIL or FasL. The polypeptide of the invention comprises a sequence -W-S-A1-C-S-A2-C-G- wherein A1 and A2 are amino acid sequences comprising 1 to 5 amino acids. More particularly, the invention relates to said polypeptide for inhibiting or preventing the apoptosis associated with a disease selected from the group consisting of neurodegenerative disorders, cerebral ischemia, neuronal traumas, neuronal inflammatory diseases, and viral neurodegenerations. | 07-21-2011 |
20110177063 | METHODS FOR TREATING COLORECTAL CANCER - The present disclosure is directed to methods of treating and preventing colorectal cancer metastasis or recurrence of colorectal cancer with compositions comprising anti-progastrin antibodies. | 07-21-2011 |
20110165166 | LSR RECEPTOR, ITS ACTIVITY, ITS CLONING, AND ITS APPLICATIONS TO THE DIAGNOSIS, PREVENTION AND/OR TREATMENT OF OBESITY AND RELATED RISKS OR COMPLICATIONS - The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines. | 07-07-2011 |
20110136823 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF - The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy. | 06-09-2011 |
20110130338 | USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES - This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor. | 06-02-2011 |
20110118317 | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism - The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect. | 05-19-2011 |
20110046233 | GOSSYPOL DERIVATIVES, PRODUCTION METHOD THEREOF AND USES OF SAME - The present invention relates to compounds of general formula (1): | 02-24-2011 |
20110044899 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS - A compound of formula (I): in which R | 02-24-2011 |
20110039708 | MOLECULAR CLASSIFIER FOR PROGNOSIS IN MULTIPLE MYELOMA - The invention relates to a 15-gene molecular classifier consisting of the following genes: CNDP2; STMN1; AFG3L2; STK38; PARP1; CPSF6; LOC151162; C20orf100; FRY; FLJ21438; MGST1; ALDH2; CTSF; ATF4; FAM49A. The level of expression of these genes in bone marrow plasma cells of patients with multiple myeloma is a useful marker for evaluating their probability of survival. | 02-17-2011 |
20110034540 | Use of the CYP46A1 Gene for the Treatment of Alzheimer's Disease - The invention relates to a viral vector for treating Alzheimers disease, which vector comprises a cholesterol 24-hydroxylase (CYP46A1) encoding nucleic acid. In a preferred embodiment, the viral vector may be an Adeno-Associated-Virus (AAV) vector, preferably an AVV5 vector. The vector may be useful for the manufacture of a pharmaceutical composition for the treatment of Alzheimers disease in a subject, wherein the vector is to be administered directly into the brain of the subject or by intravenous or intrathecal injection. | 02-10-2011 |
20110014691 | METHOD FOR GENERATING PRIMATE CARDIOVASCULAR PROGENITOR CELLS FOR CLINICAL USE FROM PRIMATE EMBRYONIC STEM CELLS OR EMBRYONIC-LIKE STATE CELLS, AND THEIR APPLICATIONS - The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention. | 01-20-2011 |
20110008296 | MUSCLE-DERIVED CELLS HAVING DIFFERENTIATION CAPACITIES - The present application relates to cell populations having differentiation capacities, which are obtainable by isolation from a muscle tissue, more particularly from a skeletal and/or cardiac muscle tissue, preferably from endomysial and/or cardiac tissue, more preferably from endomysial tissue. The cell populations of the invention comprise ALDH-positive cells, and notably have myogenic and/or adipogenic and/or osteogenic differentiation capacities. | 01-13-2011 |
20100316572 | USE OF FSH RECEPTOR LIGANDS FOR DIAGNOSIS AND THERAPY OF CANCER - The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells. | 12-16-2010 |
20100311695 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR TARGETING BONE TISSUE - The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C | 12-09-2010 |
20100303779 | Non-Conventional NKT Cells for Use in Cancer Therapy - The invention relates to the use of CD Id-independent NKT cells, for the preparation of a pharmaceutical composition for treating a tumor in a patient. Said CD1d-independent NKT cells may be obtained by (a) culturing a population of T cells under conditions which suppress TGFβ signalling pathway, and (b) selecting the cells which exhibit at least one NK marker. | 12-02-2010 |
20100297247 | Aqueous-Core Lipid Nanocapsules for Encapsulating Hydrophilic and/or Lipophilic Molecules - The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:—an oil phase;—in said oil phase,—an aqueous droplet, or—a nanocapsule (NC) comprising:—an aqueous core, and—a polymeric shell or a shell composed of an amphiphilic substance; and—a surfactant. This composition is particularly useful for encapsulating hydrophilic and/or lipophilic substances. | 11-25-2010 |
20100260724 | METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF - The invention relates to a method for measuring the plasmine activity of microparticles, in particular circulating microparticles, in a sample of a biological fluid, particularly a biological fluid in a flow situation, wherein said method can be used as a diagnosis method or a method for following a treatment. | 10-14-2010 |
20100240084 | USE OF THE PROTIEN MABA (FABG1) OF MYCOBACTERIUM TUBERCULOSIS FOR DESIGNING AND SCREENING ANTIBIOTICS - The protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The uses of proteins MabA, or recombinant proteins derived from protein MabA by mutation of at lease one amino acid, proteins and to the crystalloghraphis co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of these proteins, and advantageously, ligands inhibiting the enzymatic activity of these proteins. | 09-23-2010 |
20100222418 | Combination Products For Treating Cancer - The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. | 09-02-2010 |
20100209917 | POLYMORPHIC LENGTH OF FOXE1 ALANINE STRETCH AND GENETIC SUSCEPTIBILITY TO THYROID DYSGENESIS - The present invention concerns a method for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) for an individual, wherein said method comprises determining the length of the polyalanine repeat of the protein encoded by at least one allele of the FOXE1 (Forkhead box E1) gene in a tissue sample obtained from said individual; and a kit for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) in an individual comprising at least one nucleic acid probe or oligonucleotide which can be used in such a method. | 08-19-2010 |
20100203080 | Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof - The invention concerns a mixture of peptides derived from the E6 and/or E7 proteins of a papillomavirus involved in cervix of uterus cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57, and HPV58, for example, as well as its uses as medicine (in immunogenic compositions, capable of stimulating the production of anti-HPV T CD4+ lymphocytes in vivo and hence useful for vaccination against uterine of uterus cancer and in other cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in particular for assessing the immune condition of patients. The invention also concerns a mixture of peptides derived from E6 and/or E7 proteins of a papillomavirus involved in benign skin lesions (for example warts), such as HPV10, HPV3 or HPV4 and its uses as medicine. | 08-12-2010 |
20100197578 | DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A - There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies. | 08-05-2010 |
20100196586 | FOODSTUFF COMPOSITION TO IMPROVE DIGESTIBILITY OF FOODSTUFF LIPIDS - The invention relates to human or animal food and more particularly to a food composition for improving digestibility of foodstuff lipids, comprising one or more lysophospholipids and/or phospholipids. The invention further relates to a foodstuff containing said food composition and a method for improving the digestibility of foodstuff lipids. | 08-05-2010 |
20100179212 | Pharmaceutical composition which improves in vivo gene transfer - A pharmaceutical composition which combines a tetrafunctional copolymer with a nucleic acid, said copolymer having formula I (namely a poloxamine), and preferably taking the form of one of the cationic mineral or organic salts thereof. The composition can be used to improve in vivo gene transfer. | 07-15-2010 |
20100129839 | Method for in vitro diagnosis of pvl-producing staphylococcus aureus - The present invention relates to a method for in vitro diagnosis of | 05-27-2010 |
20100093007 | Method of Diagnosis of Tuberculosis Related Immune Restoration Syndrome (IRS) - The present invention relates to a method and kit of diagnosis of Immune Restoration Syndrome associated with tuberculosis (TB-IRS) in patients infected with tuberculosis (TB) as well as in HIV co-infected patients comprising detecting an acute increase in Th1 response following exposure to mycobacterial extract, referred as tuberculin or PPD (Purified Protein Derivative) as well as to the 16 kDa protein, but not to ESAT-6 or CFP-10, two antigens from | 04-15-2010 |
20100061928 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS - The present invention relates to the use of a compound of formula (I): | 03-11-2010 |
20100040540 | ANTI CD44 ANTIBODIES FOR ERADICATING LEUKAEMIC STEM CELLS AND BREAST CANCER STEM CELLS - The present invention provides the use of an anti-CD44 antibody, a (Fab′)2, Fab, Fab′ fragment thereof, an IgG or IgM isotype thereof, in a method for eradicating pathological stem cells in cancer therapy, and more specifically in breast cancer and leukaemia therapy. | 02-18-2010 |
20100035974 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF - The present invention relates to a composition comprising a siRNA and a transfecting compound consisting of an aminoglycoside of the class of 4,5-disubstituted 2-deoxystreptamine ring linked via a spacer molecule to a lipid moiety of formula —(R1)R2 wherein R1 and R2 represent, independently of one another, a hydrogen atom or a fatty aliphatic chain or R1 or R2 is absent, with the proviso that at least one of R1 and R2 represents a fatty aliphatic chain; or —OR3 or —NR3 wherein R3 represents a steroidal derivative. The invention also concerns in vitro and in vivo applications of these compositions. | 02-11-2010 |
20100016235 | Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof - The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer. | 01-21-2010 |
20090317815 | Mononucleotide repeats microsatellite markers for detecting microsatellite instability - A method for evaluating microsatellite instability associated with a tumour, which entails the steps of amplifying microsatellite loci in a biological sample containing genomic DNA from the tumour and determining sizes of DNA amplification products, wherein at least one microsatellite locus selected from the group consisting of NR 21, NR 22, NR 24 and NR 27, is amplified. | 12-24-2009 |
20090317797 | Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis - The invention relates to a non-invasive, prenatal, in-vitro method for detecting the normal healthy condition, the condition of a healthy carrier or the condition of a carrier inflicted with cystic fibrosis, from the fetal cell(s) from a maternal sample, comprising the DNA of an individual to be tested. The invention also relates to oligonucleotide primers and to their use within the scope of a non-invasive, prenatal, in-vitro method for detecting the condition of a healthy carrier or of a carrier inflicted with cystic fibrosis. | 12-24-2009 |
20090305275 | DNAs AND PROTEINS OR PEPTIDES SPECIFIC TO BACTERIA OF THE SPECIES NEISSERIA MENINGITIDIS, PROCESS FOR OBTAINING THEM AND THEIR BIOLOGICAL USES - The DNA of the invention are characterised in that they concern the whole or pan of genes, with their reading frame, to be found in | 12-10-2009 |
20090298713 | POLYNUCLEOTIDES WHICH ARE OF NATURE B2/D+ A- AND WHICH ARE ISOLATED FROM E. COLI, AND BIOLOGICAL USES OF THESE POLYNUCLEOTIDES AND OF THEIR POLYPEPTIDES - The present invention relates to products which are of nature B2+ A−, isolated from | 12-03-2009 |
20090269363 | METHOD FOR SCREENING PEPTIDES FOR USE IN IMMUNOTHERAPY - Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa). | 10-29-2009 |
20090263847 | LSR RECEPTOR, ITS ACTIVITY, ITS CLONING AND ITS APPLICATIONS TO THE DIAGNOSIS, PREVENTION AND/OR TREATMENT OF OBESITY AND RELATED RISKS OR COMPLICATIONS - The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines. | 10-22-2009 |
20090232826 | Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 - The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or functional analogues thereof. | 09-17-2009 |
20090221476 | Peptide Capable of Altering Tubulin Polymerization and use Thereof for Inhibiting Cell Proliferation - The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example. | 09-03-2009 |
20090208963 | Gene Involved in V(D)J recombination and/or DNA repair - The invention relates to a new gene and protein involved in V(D)J recombination and repair. The invention also relates to methods of diagnosis and therapy using these genes and protein. The invention also relates to transgenic animals over- and under-expressing said gene. | 08-20-2009 |
20090202979 | Production of antibody formats and immunological applications of said formats - The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell. | 08-13-2009 |
20090175871 | METHOD FOR DEMONSTRATING PRESENCE OR ABSENCE OF MARKERS ASSOCIATED WITH THE PRESENCE AND/OR THE CHEMOSENSITIVITY OF TUMORS - A method for detecting presence or absence of a tumor in a mammal and/or its sensitivity to chemotherapies, including, on a biological sample from said mammal, detecting and/or quantifying: presence of an eEF1A1 protein, and/or presence of antibodies directed against an eEF1A1 protein or a fragment including at least one epitope of eEF1a1 protein, and/or presence of a MARK3 protein, and/or presence of antibodies directed against a MARK3 protein or a fragment comprising at least one epitope of the MARK3 protein. | 07-09-2009 |
20090170749 | Novel Compounds Which Interact With PEA-15 - The present invention relates to novel pseudopeptide compounds of defined formula, capable of interacting with the PEA-15 protein and to the use thereof in screening methods and to a method of diagnosing pathological conditions which may involve PEA-15. | 07-02-2009 |
20090156541 | DBAIT AND USES THEREOF - The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses novel double-stranded nucleic acid molecules. that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non homologous end joining (NHEJ) pathway of DSB repair. | 06-18-2009 |
20090155173 | PERSISTENT LUMINESCENCE NANOPARTICLES USED IN THE FORM OF A DIAGNOSIS AGENT FOR IN VIVO OPTICAL IMAGING - The invention relates to using persistent luminescence nanoparticles, functionalised if necessary, in the form of an diagnosis agent for an in vivo optical imaging. Said nanoparticles are preferably consist of a compound selected from a group comprising (1) silicates, aluminates, aluminosilicates, germanates, titanates, oxysulphides, phosphates and vanadates, wherein said compounds contain at least one type of metal oxide, (2) the sulphides comprise at least one metal ion selected from zinc, strontium and calcium, and (3) metal oxides, wherein said compounds is doped with at least one rare earth ion, and possibly with at least one transition metal ion. In a preferred embodiment, the diagnosis agent is used for an organism vascularisation imaging. A method and kit for detecting or quantifying in vitro a substance of biological or chemical interest in a sample by using said pre-functionalised nanoparticles are also disclosed. | 06-18-2009 |
20090149464 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases - Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them. | 06-11-2009 |
20090130689 | Method useful for detecting encephalopathies - The invention concerns a method of detecting a TSSE Disease or prion disease. The invention further concerns a method for amplifying oligomerization of isoforms of the cellular prion PrP | 05-21-2009 |
20090124630 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS - The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders. | 05-14-2009 |
20090118180 | USE OF FUSION PROTEINS FOR THE PREVENTION OR THE TREATMENT OF PATHOLOGIES RESULTING FROM ISCHEMIA - The present invention relates to the use of a fusion protein including a peptide sequence having membrane transducing properties, and a peptide sequence having cell survival properties, or a nucleic acid coding for the fusion protein, for the manufacture of a medicament intended for the prevention or the treatment of pathologies resulting from ischemia. | 05-07-2009 |
20090117110 | Method for the In Vitro Assessment of the Progression Status of an Infection by an HIV Virus in an Individual - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. | 05-07-2009 |
20090104188 | ANTI-HEPATITIS C VIRUS ANTIBODY AND USES THEREOF - Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable of neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation. | 04-23-2009 |
20090087449 | Novel Peptide Compositions and the Use Thereof, in Particular, in the Preparation of Active Pharmaceutical Compositions Against the Hepatitis C Virus - The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID NO 1, a peptide B having at least the amino acid sequence of SEQ ID NO 45, a peptide C having at least the amino acid sequence of SEQ ID NO 127, and a peptide D having at least the amino acid sequence of SEQ ID NO 174. The inventive compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus. | 04-02-2009 |
20080268476 | Nectin 4 (N4) as a Marker for Cancer Prognosis - The present invention relate for a method for prognosis cancer, in particular metastatic breast cancer comprising doing a dosage of Nectin 4, in a soluble form or in transmembrane form, in a sample, the presence of Nectin 4 being indicative of a cancer. | 10-30-2008 |
20080248044 | POLYEPITOPIC PROTEIN FRAGMENTS OF THE E6 AND E7 PROTEINS OF HPV, THEIR PRODUCTION AND THEIR USE PARTICULARLY IN VACCINATION - Polyepitopic peptides of E6 and E7 proteins of Human Papillomavirus, their production, and methods of treating pathologies in which a polyepitopic peptide of the E6 and E7 protein of Human Papillomavirus is recognized by the cellular immune system. | 10-09-2008 |